Us Fda Grants Accelerated Approval To Gileada

Gilead Sciences Announced That The Us Food And Drug Administration (Fda) Has Granted Accelerated Approval Of Trodelvy (Sacituzumab Govitecan-Hziy) For Use In Adult Patients With Locally Advanced Or Metastatic Urothelial Cancer (Uc) Who Have Previously Received A Platinum-Containing Chemotherapy And Either A Programmed Death Receptor-1 (Pd-1) Or A Programmed Death-Ligand 1 (Pd-L1) Inhibitor.The Accelerated Approval Was Based On Data From The International Phase 2, Single-Arm Trophy Study. Of The 112 Patients Who Were Evaluable For Efficacy, 27.7% Of Those Treated With Trodelvy Responded To Treatment, With 5.4% Experiencing A Complete Response And 22.3% Experiencing A Partial Response. The Median Duration Of Response Was 7.2 Months (95% Ci: 4.7-8.6).The Fda&Rsquo;S Accelerated Approval Mechanism Enables Drugs That Treat Serious Diseases With Unmet Medical Need To Be Approved Based On A Surrogate Or Intermediate Clinical Endpoint. Continued Approval Is Contingent Upon Verification And Description Of Clinical Benefit In A Confirmatory Trial.&Ldquo;Only A Fraction Of Patients Derives Long-Term Benefit From Previously Approved Cytotoxic Therapy Or Immunotherapy, Leaving A Great Unmet Need For Treatment Options For Patients With Advanced Urothelial Cancer Who Have Progressed On First- And Second-Line Therapies,&Rdquo; Said Scott T. Tagawa, Md, Ms, Facp, Professor Of Medicine And Urology At Weill Cornell Medicine, An Oncologist At New York-Presbyterian/Weill Cornell Medical Center And Principal Investigator Of The Trophy Study.I &Ldquo;The Response Rate And Tolerability Seen With Sacituzumab Govitecan-Hziy May Provide Physicians An Effective New Treatment Option For Patients Whose Cancer Continues To Progress Even After Multiple Therapies.&Rdquo;Uc Is The Most Common Type Of Bladder Cancer And Occurs When The Urothelial Cells That Line The Inside Of The Bladder And Other Parts Of The Urinary Tract Grow Unusually Or Uncontrollably. An Estimated 83,000 Americans Will Be Diagnosed With Bladder Cancer In 2021, And Almost 90% Of Those Diagnoses Will Be Uc. The Relative Five-Year Survival Rate For Patients With Metastatic Uc Is 5.5%.&Ldquo;Cases Of Urothelial Cancer Continue To Rise In The Us, Yet Prognosis Remains The Same For The Vast Majority Of Patients,&Rdquo; Said Andrea Maddox-Smith, Ceo Of The Bladder Cancer Advocacy Network (Bcan). &Ldquo;Bladder Cancer Patients Need As Many Treatment Options As Possible, And We Are Pleased That Trodelvy Can Be A Potentially Viable Treatment For Them.&Rdquo;Trodelvy&Rsquo;S Safety Profile In The Trophy Study Is Consistent With Previous Observations In Metastatic Uc And Other Tumor Types. Among All Evaluable Treated Metastatic Uc Patients (N=113), The Most Common (=25%) Adverse Reactions Were Diarrhea (72%), Anemia (71%), Fatigue (68%), Neutropenia (67%), Nausea (66%), Alopecia (49%), Decreased Appetite (41%), Constipation (34%), Vomiting (34%) And Abdominal Pain (31%). Adverse Reactions Leading To Treatment Discontinuation Occurred In 10% Of Those Receiving Trodelvy, With 4% Discontinuing Treatment Due To Neutropenia.&Ldquo;Today&Rsquo;S Accelerated Approval Is Thanks To The Patients And Healthcare Professionals Involved In The Trophy Study, And We Appreciate Their Partnership,&Rdquo; Said Merdad Parsey, Md, Phd, Chief Medical Officer, Gilead Sciences. &Ldquo;This Achievement, Coupled With Last Week&Rsquo;S Full Fda Approval In Unresectable Locally Advanced Or Metastatic Triple-Negative Breast Cancer, Underscores Our Commitment Toward Rapidly Delivering Trodelvy To Patients Facing Some Of The Most Difficult-To-Treat Cancers.&Rdquo;Trodelvy (Sacituzumab Govitecan-Hziy) Is A First-In-Class Antibody And Topoisomerase Inhibitor Conjugate Directed To The Trop-2 Receptor, A Protein Frequently Expressed In Multiple Types Of Epithelial Tumors, Including Metastatic Triple-Negative Breast Cancer (Tnbc) And Metastatic Uc, Where High Expression Is Associated With Poor Survival And Relapse.The Phase 2 Trophy-U01 (Also Known As Immu-132-06) Trial Is An Ongoing, International, Multi-Center, Open-Label, Multi-Cohort, Single-Arm Study Evaluating Trodelvy Monotherapy Or Combination Therapy In Patients With Metastatic Uc After Progression On A Platinum-Based Regimen And Anti-Pd-1/Pd-L1-Based Immunotherapy. In Cohorts 1 And 2, Patients Received Trodelvy 10 Mg/Kg Administered Intravenously On Days 1 And 8 Of A 21-Day Cycle To Be Continued Until Disease Progression Or Loss Of Clinical Benefit. Trodelvy Is Approved Under Accelerated Approval Based On The Objective Response Rate (Orr) And Duration Of Response (Dor) Established In Cohort 1.Cohorts 2, 3, 4 And 5 Of The Study Are Ongoing. Cohort 2 Is Assessing The Safety And Efficacy Of Trodelvy Monotherapy In Platinum-Ineligible Patients After Progression On Anti-Pd-1/Pd-L1-Based Immunotherapy. Cohort 3 Is Assessing The Safety And Efficacy Of Trodelvy On Days 1 And 8 Of A 21-Day Cycle Followed By Pembrolizumab At The Standard Approved Dose (200 Mg) Only On Day 1 Of A 21-Day Cycle In Patients With Metastatic Uc Who Have Progressed After Prior Platinum Therapy. Cohorts 4 And 5 Are Assessing The Safety And Efficacy Of Trodelvy Combination Therapy In Patients With Treatment Naive Metastatic Uc, With Those In Cohort 4 Receiving Cisplatin And Those In Cohort 5 Receiving Cisplatin And Avelumab, Respectively, In Addition To Trodelvy.The Primary Endpoint Is Orr Based On Recist 1.1 Criteria Evaluated By Independent Central Review In All Five Cohorts. In Cohorts 1 And 2, Secondary Endpoints Are Dor And Progression-Free Survival (Pfs) Based On Central Review And Overall Survival (Os). Secondary Endpoints In Cohorts 3, 4 And 5 Include Dor, Clinical Benefit Rate (Cbr) And Pfs Based On Central Review By Recist 1.1 Criteria; Dor, Cbr And Pfs Based On Investigator Review By Recist 1.1 And Irecist Criteria, Os And Safety And Tolerability Of Trodelvy In Combination With Pembrolizumab, Cisplatin, Or Cisplatin And Avelumab, Depending On The Cohort.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!